article · Benha Journal of Applied Sciences
Background: The burden of pediatric cardiac arrhythmias is variable and can lead to morbidity and mortality. Many biomarkers are related to cardiovascular diseases. Fibroblast growth factor 23 (FGF-23) is an example for important biomarkers in arrhythmia. It is formed in bone and is related to mineral bone metabolism. Elevated levels of this factor were correlated with chronic renal disease and many cardiovascular diseases. Many studies correlated FGF-23 with arrhythmia particularly atrial fibrillation and revealed that it may be used as a prognostic biomarker in those patients. Knowledge of FGF-23 role in cardiovascular problems may be used to discover new methods in management of these disorders. Objective: The aim of this review is to shed light on pediatric cardiac arrhythmia and to study the importance of biomarkers in cardiovascular diseases particularly cardiac arrhythmia and study its relationship with prognosis and cardiac function. Keywords: Fibroblast growth factor-23, Cardiac arrhythmia, Biomarkers, Atrial fibrillation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/bjas.2024.303093.1453
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.